Compare Adaptive Biotechnologies Corp (ADPT) vs Bilibili Inc (BILI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Bilibili Inc — how do they compare? Adaptive Biotechnologies Corp trades at $25.03 (market cap $4.04B), while Bilibili Inc trades at $17.52 (market cap $7.65B). The key difference: Bilibili Inc is the larger of the two by market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Bilibili Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | BILI | |
|---|---|---|
Market Cap | $4.04B | $7.65B |
Sector | Health | Media |
52-Week High | $25.45 | $35.92 |
52-Week Low | $12.30 | $15.96 |
Enterprise Value | $4.10B | $5.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.94, down 2.0% today but near its 52-week high. The stock shows a bullish technical trend with improving fundamentals, including 49% MRD revenue growth and narrowing losses. A recent 4:1 reverse stock split and planned business separation aim to unlock value, with analyst consensus leaning bullish.
Outlook is cautiously optimistic due to strong revenue growth and margin expansion, but risks persist from ongoing net losses and competitive pressures. The stock offers potential upside to the $25.50 consensus target if execution continues improving, yet volatility may remain until profitability is achieved.
Bilibili (BILI) trades at $17.48, down 7.95% over 24 hours, reflecting bearish technical momentum. The stock shows strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.19 versus $0.17 expected, and revenue growth to $30.35 billion in 2025. Analyst sentiment remains overwhelmingly bullish with 20 buy ratings out of 24, supported by a $300 million share repurchase program announced June 24, 2026.
The outlook is positive given robust user engagement and advertising growth, but risks include competitive pressures and reliance on Chinese market dynamics. Valuation metrics like a P/E of 36.24 suggest premium pricing, requiring sustained execution to justify upside. Near-term focus is on Q2 2026 earnings due August 27, 2026, which could catalyze movement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Bilibili Inc
Bilibili is a leading video sharing and online entertainment platform for Gen Z in China. It offers a diverse range of content, including anime, games, and live broadcasting, fueled by a highly engaged community.
Read more on BILI →
